Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
BACKGROUND: We conducted a phase I/II clinical trial to evaluate the efficacy of eribulin and olaparib in a tablet form (EO study) for triple-negative breast cancer (TNBC) patients. We hypothesized that somatic BRCA mutations and homologous recombination repair (HRR)-related gene alterations might a...
Main Authors: | Akihiko Shimomura, Kan Yonemori, Masayuki Yoshida, Teruhiko Yoshida, Hiroyuki Yasojima, Norikazu Masuda, Kenjiro Aogi, Masato Takahashi, Yoichi Naito, Satoru Shimizu, Rikiya Nakamura, Akinobu Hamada, Hirofumi Michimae, Jun Hashimoto, Harukaze Yamamoto, Asuka Kawachi, Chikako Shimizu, Yasuhiro Fujiwara, Kenji Tamura |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-10-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523319302037 |
Similar Items
-
Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study
by: Sakura Iizumi, et al.
Published: (2017-12-01) -
Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer.
by: Natsuko Satomi-Tsushita, et al.
Published: (2019-01-01) -
Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort
by: Harano, K., et al.
Published: (2022) -
Eribulin drug review
by: Nishitha Shetty, et al.
Published: (2014-01-01) -
Eribulin in Cancer Treatment
by: Umang Swami, et al.
Published: (2015-08-01)